LivaNova (LIVN)
NASDAQ: LIVN
· Real-Time Price · USD
43.23
0.06 (0.14%)
At close: May 30, 2025, 3:59 PM
43.25
0.05%
After-hours: May 30, 2025, 04:21 PM EDT
LivaNova Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Cardiopulmonary Segment Revenue | 683.51M | 588.98M | 500.31M | 482.98M | 354.44M | 424.55M |
| Cardiopulmonary Segment Revenue Growth | +16.05% | +17.72% | +3.59% | +36.26% | -16.51% | n/a |
| Neuromodulation Segment Revenue | 554.22M | 519.71M | 476.99M | 456.17M | n/a | n/a |
| Neuromodulation Segment Revenue Growth | +6.64% | +8.96% | +4.56% | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 220.03M | 214.79M | 178.8M | 201.53M | 193.37M | 223.18M | 210.47M | 402.07M |
| Europe Revenue Growth | +2.44% | +20.13% | -11.28% | +4.22% | -13.36% | +6.04% | -47.65% | n/a |
| Locations Excluding The United States And Europe Revenue | 338.32M | 303.71M | 271.44M | 262.54M | 272.24M | 546.48M | 494.72M | 490.51M |
| Locations Excluding The United States And Europe Revenue Growth | +11.40% | +11.89% | +3.39% | -3.56% | -50.18% | +10.46% | +0.86% | n/a |
| United States Revenue | 695.08M | 635.04M | 571.56M | 571.3M | 468.63M | n/a | n/a | n/a |
| United States Revenue Growth | +9.45% | +11.11% | +0.05% | +21.91% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Oct 18, 2015 | Sep 30, 2015 | Apr 30, 2015 | Jan 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 133.67M | 135.62M | 131.66M | 129.12M | 129.86M | 133.3M | 134.8M | 125.9M | 124.1M | 119.6M | 114.63M | 116.5M | 118.53M | 124.4M | 109.04M | 122.75M | 112.62M | 110.3M | 99.2M | 98.05M | 120.2M | 130.6M | 123.02M | 127.21M | 125.7M | 122.2M | 115.14M | 123.4M | 104.2M | 101.6M | 121.18M | 120.37M | 112.4M | 123.5M | 107.55M | 120.2M | 115.6M | 41.19M | 33.71M | 30.41M | 31.33M |
| Selling, General, and Administrative Revenue Growth | -1.44% | +3.01% | +1.97% | -0.57% | -2.58% | -1.11% | +7.07% | +1.45% | +3.76% | +4.34% | -1.61% | -1.71% | -4.72% | +14.08% | -11.17% | +9.00% | +2.10% | +11.19% | +1.17% | -18.43% | -7.96% | +6.17% | -3.30% | +1.20% | +2.87% | +6.14% | -6.70% | +18.43% | +2.56% | -16.16% | +0.67% | +7.09% | -8.99% | +14.83% | -10.52% | +3.98% | +180.68% | +22.19% | +10.82% | -2.92% | n/a |
| Research and Development Revenue | 37.88M | 43.31M | 48.8M | 44.74M | 41.86M | 46.2M | 46.5M | 51.1M | 50M | 44.9M | 35.73M | 34.2M | 40.92M | 44.1M | 42.13M | 52.56M | 44.63M | 44.5M | 47.37M | 25.15M | 35.9M | 25.9M | 45.9M | 34.54M | 43.58M | 37.6M | 42.42M | 34.2M | 31.8M | 32.5M | 31.39M | 43.01M | 29.65M | 28.4M | 32.17M | 30.2M | 31.7M | 15.25M | 10.06M | 11.37M | 10.53M |
| Research and Development Revenue Growth | -12.54% | -11.26% | +9.09% | +6.86% | -9.39% | -0.65% | -9.00% | +2.20% | +11.36% | +25.68% | +4.46% | -16.42% | -7.22% | +4.67% | -19.83% | +17.77% | +0.28% | -6.05% | +88.33% | -29.94% | +38.61% | -43.58% | +32.89% | -20.73% | +15.89% | -11.36% | +24.03% | +7.55% | -2.15% | +3.53% | -27.00% | +45.04% | +4.40% | -11.73% | +6.54% | -4.73% | +107.88% | +51.56% | -11.55% | +8.02% | n/a |